Group items tagged

This announcement solicits applications for the Rural Opioid Overdose Reversal (ROOR) Grant Program. The purpose of the ROOR program is to reduce the incidences of morbidity and mortality related to opioid overdoses in rural communities through the purchase and placement of emergency devices used to rapidly reverse the effects of opioid overdoses and the training of licensed healthcare professionals and emergency responders on the use of opioid devices. Community partnerships are an important component of this program and can be comprised of local emergency responders as well as other local non-profit and for-profit entities involved in the prevention and treatment of opioid overdoses. In addition, care coordination is essential to efforts in reducing incidences of morbidity and mortality related to opioid overdoses. As a result, this funding opportunity announcement is seeking innovative approaches that involve broad community partnerships which may include referral of individuals to appropriate substance abuse treatment centers where care coordination and communication is facilitated by a team of qualified health care providers. The ROOR goals are to: 1) Purchase naloxone and opioid overdose reversal devices and increase the availability in rural areas through strategic placement; 2) Train licensed healthcare professionals and others using the devices to recognize the signs of opioid overdose, administer naloxone, administer basic cardiopulmonary life support, report results, and provide appropriate transport to a hospital or clinic for continued care after administration; 3) Refer those with a drug dependency to appropriate substance abuse treatment centers where care coordination is provided by a team of providers; and Demonstrate improved and measurable health outcomes, including but not limited to, reducing opioid overdose morbidity and mortality in rural areas.

The purpose of this program is to provide funding to states to enhance/expand their treatment service systems to increase capacity and provide accessible, effective, comprehensive, coordinated care, and evidence-based medication assisted treatment (MAT) and recovery support services to individuals with opioid use disorders seeking or receiving MAT. As a result of this program, SAMHSA seeks to: 1) increase the number of individuals receiving MAT services with pharmacotherapies approved by the FDA for the treatment of opioid use disorders; 2) increase the number of individuals receiving integrated care; and 3) decrease illicit drug use at 6-months follow-up. For the purpose of this RFA, integrated care is defined as the organized delivery and/or coordination of medical, behavioral or social and recovery support services provided to individual patients in order to produce better overall health outcomes for people that may have multiple healthcare needs. MAT is defined as the use of FDA-approved opioid agonist medications (e.g., methadone, buprenorphine products including buprenorphine/naloxone combination formulations and buprenorphine mono-product formulations) for the maintenance treatment of opioid use disorder and opioid antagonist medication (e.g., naltrexone products including extended-release and oral formulations) to prevent relapse to opioid use. MAT includes screening, assessment (which includes determination of severity of opioid use disorder, including presence of physical dependence and appropriateness for MAT) and case management. MAT is to be provided in combination with comprehensive substance use disorder treatment, including but not limited to: counseling, behavioral therapies and when needed pharmacotherapy for co-occurring alcohol use disorder. MAT is to be provided in a clinically driven, person-centered and individualized setting. Priority will be given to states (listed in Appendix V) that have not only demonstrated a high rate of primary treatme

Undertake research activities that would entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic; and Support and promote the partnership of law enforcement and public health agencies, whose collaboration is critical to reducing overdose and other harms of opioid (mis)use. This ongoing opioid overdose epidemic presents new challenges to public health and public safety officials, medical professionals, local communities, and other stakeholders invested in curbing rates of accidental death. Preparing regional and community leaders to respond effectively to the public health emergency that is today's opioid overdose crisis (and be prepared to take on that crisis as it evolves tomorrow) is essential for achieving the shared goal of preventing fatal overdose and saving lives. ONDCP expects to award one Federal grant under the Combating Opioid Overdose through Community-Level Intervention Initiative for a 1-year period, beginning approximately September 2017. The successful non-Federal entity (NFE) will conduct research activities that entail implementing and evaluating community-based efforts to fight the opioid overdose epidemic. These activities will be focused on the regions of the United States with some of the highest rates of fatal and non-fatal opioid-related overdoses and will work to coordinate the often decentralized state and local efforts to assess and respond to opioid-related overdoses.

The National Institute on Drug Abuse (NIDA) intends to publish a series of Funding Opportunity Announcements (FOA) for Cooperative Agreements to solicit applications for a network of researchers collaborating across justice and community-based service settings to transform community-level responses to opioid misuse and opioid use disorder (OUD) in justice-involved populations. Opioid misuse and opioid use disorder consequences exist at the intersection of health and justice systems. Improving the capacity of the justice system to respond to opioid crisis with evidence-based approaches that include the use of medications for OUD requires strong partnerships between justice systems and healthcare as well as other community based organizations. Supporting the development of these relationships and novel models of justice-healthcare and otherncommunity collaboration is a critical target in addressing the current opioid crisis. NIDA is interested in launching a network of investigators who can rapidly conduct research to address the opioid crisis in justice settings. A variety of research methods will be used, including clinical trials, implementation science research, policy evaluations and/or modeling approaches. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. This FOA is expected to use a multicomponent cooperative agreement mechanism. The FOA is expected to be published in October 2018 with an expected application due date in December 2018.

The awards pursuant to this Notice of Funding Opportunity are contingent upon the availability of funds. The Centers for Disease Control and Prevention's National Center for Injury Prevention and Control (NCIPC) is soliciting investigator-initiated research that will help expand and advance our understanding about what works to prevent overdose from prescription and illicit opioids by developing and piloting, or rigorously evaluating novel primary or secondary prevention interventions. The intent of this Notice of Funding Opportunity (NOFO) is to: (1) build the scientific base for the primary or secondary prevention of opioid overdose, and (2) encourage collaboration of scientists from a spectrum of disciplines including public health, epidemiology, law enforcement, social work, economics, and criminal justice to perform research that can identify ways to prevent opioid overdose more effectively. Interventions can be strategies, programs, or policies. Ultimately, this research is intended to improve state and local health departments’ ability to implement and improve interventions focused on preventing opioid-related deaths. Researchers are expected to develop and pilot, or rigorously evaluate novel primary or secondary prevention interventions that address prescription or illicit opioid overdose. Primary prevention approaches are expected to aim to prevent opioid misuse, abuse, and overdose before it occurs. Secondary prevention approaches are expected to focus on the more immediate responses to opioid overdose, such as emergency department services and linkage to treatment immediately following a nonfatal overdose.

The purpose of this FOA is to fund a single interdisciplinary Coordinating Center to formalize and centralize support of the rural opioid initiative administered by NIDA and co-funded by CDC, SAMHSA, and ARC. This initiative was funded under RFA-DA-17-014 and RFA-DA-17-023 The Coordinating Center will provide scientific, technical, regulatory, ethical, and logistical support of data comparability, new data collection, and data integration; developing integrated rural opioid initiative datasets; assisting grantees with acquisition and analysis of local administrative and/or research datasets that enable evaluation of their implementation activities or augment their community assessments; conducting requested analyses that relate to the integrated rural opioid initiative datasets; developing and executing a rural opioid initiative publication and dissemination plan; and providing logistical support for in-person meetings, conference calls, and webinars that include the rural opioid initiative grantees and funders. The Coordinating Center will be represented on the rural opioid initiative executive steering committee, along with the funders and rural opioid initiative grantees.

NIDILRR proposes to fund two Disability and Rehabilitation Research Projects of three years each to conduct research on opioid use disorder among people with disabilities. Each grant will be funded up to $500,000. Topic of interest include: 1) Systematic review of existing literature on opioid-use disorder and people with disabilities; 2) Prevalence estimates and patterns of opioid use disorder treatment for people with disabilities; 3) Factors associated with increased risk for opioid use disorder; 4) Factors associated with improved access to treatment for opioid use disorder; 5) Interventions that contribute to improved outcomes; and 6) Effects of government policies and programs on access to treatment for people with disabilities who have opioid-use disorders.

The Substance Abuse and Mental Health Services Administration (SAMHSA), Center for Substance Abuse Treatment (CSAT), is accepting applications for fiscal year (FY) 2018 Targeted Capacity Expansion: Medication Assisted Treatment - Prescription Drug and Opioid Addiction (Short Title: MAT-PDOA) grants. The purpose of this program is to expand/enhance access to medication-assisted treatment (MAT) services for persons with an opioid use disorder (OUD) seeking or receiving MAT. This program's focus is on funding organizations and tribes/tribal organizations within states identified as having the highest rates of primary treatment admissions for heroin and opioids per capita and includes those states with the most dramatic increases for heroin and opioids, based on SAMHSA's 2015 Treatment Episode Data Set (TEDS). The desired outcomes include: 1) an increase in the number of individuals with OUD receiving MAT 3) a decrease in illicit opioid drug use and prescription opioid misuse at six-month follow-up.

There is a devastating opioid use and overdose crisis in the United States. It has been reported that approximately 25.5 million adults suffer pain and opioids that are often prescribed for their treatment can lead to opioid misuse and dependence. It has also been reported that more than 2 million Americans have OUDs and many started their addiction with prescribed opioids. One of the most devastating consequences of opioid misuse is opioid overdose, which can produce respiratory depression and death. Drug overdose is the leading cause of accidental death in the US, with an estimation of 60,000 deaths in 2016; 20,101 overdose deaths related to prescription pain relievers, and 12,990 overdose deaths related to heroin.

This notice solicits applications for the Rural Communities Opioid Response Program- Planning (RCORP-Planning).  The purpose of RCORP-Planning is to support treatment for and prevention of substance use disorder, including opioid use disorder (OUD), in rural counties at the highest risk for substance use disorder. The overall goal of RCORP-Planning is to reduce the morbidity and mortality associated with opioid overdoses in high-risk rural communities by multi-sector consortiums (as defined in the  "Eligibility Information" section) planning to strengthen their organizational and infrastructural capacity to address one or more of the following focus areas at the community, county, state, and/or regional levels: Prevention:  reducing the occurrence of opioid use disorder among new and at-risk users, as well as fatal opioid-related overdoses, through activities such as community and provider education, and harm reduction measures including the strategic placement and use of overdose reversing devices, such as naloxone, and syringe services programs; (See page 20 for additional information) Treatment:  implementing or expanding access to evidence-based practices for opioid addiction/OUD treatment, such as medication-assisted treatment (MAT) including developing strategies to eliminate or reduce treatment costs to uninsured and underinsured patients; and Recovery:  expanding peer recovery and treatment options that help people start and stay in recovery. RCORP-Planning will support one (1) year of planning funding.

The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications.  Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities (15% of these fatalities must be from rural communities) and a rate of 25 opioid related overdose fatalities per 100,000 persons or higher in the past year, based on the most recent complete year of data available.

Pharmaceutical company AmerisourceBergen created the AmerisourceBergen Foundation as a separate not-for-profit charitable organization with the aim of supporting health and education-related causes that enrich the lives of its global community. To accomplish that goal, the foundation provides funding for programs and organizations focused on expanding access to quality healthcare - both human and animal - around the world. In the view of the foundation, the current epidemic of opioid abuse and misuse is a crisis that demands attention, action, and accountability. Understanding the need for expediency, the foundation is inviting grant-funded nonprofit organizations to submit proposals that describe how it can best contribute resources and funding to address opioid abuse and misuse. Grants will be awarded for the most innovative and constructive solutions in one of two key areas of focus: safe disposal and education around prevention. Applicants are strongly encouraged to identify and leverage existing, proven, evidence-based frameworks and strategies, as well as existing tools and materials, but may also propose original and innovative projects. Applications focused on education may address a spectrum of needs, but priority will be given to the effective dissemination of the following topics: provider education about appropriate opioid prescribing; patient education about the risks and effects of prescription opioids, and what to do if they have concerns about addiction; public education, especially aimed at rural communities; training to reduce youth risk factors (such as delinquency) and boost protective factors (such as decision-making skills for problem solving and resisting peer pressure; addiction as a childhood onset condition; preventing teens from initiating problematic opioid use in the first place; and advising parents of teens to lock up prescription opioid medications and dispose of old pills.

The National Institute on Drug Abuse (NIDA), in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting cooperative agreement applications with the intention of ultimately funding up to three research sites and one data coordinating center (DCC) to participate in the 'HEALing Communities Study': Developing and Testing an Integrated Approach to Address the Opioid Crisis. The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications. Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities in the past year, based on the most recent complete year of data available (15% of these deaths must be in rural communities). States within the top third for age-adjusted drug overdose death rates in 2016, (per the Centers for Disease Control) are of special interest. The integrated set of evidence-based prevention and treatment interventions should be designed to achieve the following goals: reduce overdose fatalities, and events; decrease the incidence of OUD; and increase the number of individuals receiving medication-assisted treatment, retained in treatment beyond 6 months, and receiving recovery support services compared to baseline.

The National Institute on Drug Abuse(NIDA), in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting cooperative agreement applications with the intention of ultimately funding up to three research sites and one data coordinating center (DCC) to participate in the 'HEALing Communities Study': Developing and Testing an Integrated Approach to Address the Opioid Crisis The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications. Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities in the past year, based on the most recent complete year of data available (15% of these must be from rural communities) . States within the top third for age-adjusted drug overdose death rates in 2016, (per the Centers for Disease Control) are of special interest. The integrated set of evidence-based prevention and treatment interventions should be designed to achieve the following goals: reduce overdose fatalities, and events; decrease the incidence of OUD; and increase the number of individuals receiving medication-assisted treatment, retained in treatment beyond 6 months, and receiving recovery support services compared to baseline .

The purpose of this Funding Opportunity Announcement is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose. The UG3/UH3 Phase Innovation Awards Cooperative Agreement involves 2 phases. The UG3 is to support a project with specific milestones to be accomplished by the end of the 2-year period. The UH3 is to provide funding for 3 years to a project that successfully completed the milestones set in the UG3. UG3 projects that have met their milestones will be administratively considered by NIDA and prioritized for transition to the UH3 phase. Investigators responding to this FOA must address both UG3 and UH3 phases. Application may include preclinical or clinical research studies that will have high impact and quickly yield the necessary results to advance closer to FDA approval medications that are safe and effective to prevent and treat OUDs and overdose. The compounds to be evaluated can be small molecules or biologics. They can be tested in pre-clinical models and/or for the clinical manifestations of OUDs such as withdrawal, craving, relapse, or overdose. Applications may focus on the development of new chemical entities, new formulations of marketed medications available for other indications, or combinations of medications that hold promise for the treatment of OUDs and overdose. Through this FOA, NIDA seeks to fast-track the discovery and development of medications to prevent and treat OUDs or opioid overdose and to advance them in the FDA's drug development approval pipeline. This project is part of the NIH initiative to establish a public-private partnership to address the opioid crisis via more effective and safe ways to prevent and treat opioid use disorders and overdose. https://www.nih.gov/opioid-crisis

To support generation of single cell datasets for one or more brain regions relevant to opioid use disorder and persistent HIV infection. If fully successful, this project will generate 1. A cellular parts list for selected NIDA-relevant brain regions, 2. Reveal how cell types within these brain regions differ from one another with respect to gene expression, 3. Reveal how cell types within these brain regions are altered by chronic opioid exposure providing potential novel therapeutic targets for opioid addiction, 4. Reveal how HIV infection in the CNS influences single cells, providing potential targets for improving HIV neurobiological sequelae, and 5. Uncover potential synergistic effects of chronic opioid exposure and HIV infection in the CNS.

The Comprehensive Opioid Abuse Program Training and Technical Assistance (TTA) Program establishes a comprehensive, coordinated, balanced strategy through enhanced grant programs that would expand prevention and education efforts while also promoting treatment and recovery. Through this solicitation, BJA intends to select five training and technical assistance (TTA) providers to support the Comprehensive Opioid Abuse Program (COAP). Providers will deliver TTA to tribal, state and local criminal justice and substance abuse treatment agencies nationwide, prescription drug monitoring programs (PDMPs), and their partner agencies in sites selected through the Comprehensive Opioid Abuse Site-based Program solicitation, and to communities nationwide impacted by the opioid epidemic. The TTA providers will work collaboratively within the COAP TTA Network.

he purpose of RHOP is to promote rural health care services outreach by expanding the delivery of opioid related health care services to rural communities. The program will reduce the morbidity and mortality related to opioid overdoses in rural communities through the development of broad community consortiums to prepare individuals with opioid-use disorder (OUD) to start treatment, implement care coordination practices to organize patient care activities,[1] and support individuals in recovery through the enhancement of behavioral counselling[2] and peer support activities.[3] This program will bring together health care providers (i.e. local health departments, hospitals, primary care practices, and substance abuse treatment providers) and entities such as social service and faith-based organizations, law enforcement, and other community-based groups to respond multifaceted to the opioid epidemic in a rural community. The consortium must include at least three (3) health care providers.

The National Center for Injury and Prevention Control (NCIPC) intends to provide support and 75% "protected time" for an intensive, supervised (mentored) career development experience to develop new researchers in the fields of opioid overdose prevention and cross-cutting violence prevention. The intent is to provide resources to young investigators so they can grow their skills by developing and conducting research efforts needed to address NCIPC Research Priorities (https://www.cdc.gov/injury/researchpriorities/index.html), with the potential to investigate new and emerging public health issues. Investigators focused on opioid overdose prevention must propose a research project to investigate risk factors for and strategies to prevent opioid overdose. Investigators may address one of the research gaps identified in the NCIPC Research Priorities (https://www.cdc.gov/injury/researchpriorities/index.html).

The Substance Abuse and Mental Health Services Administration (SAMHSA), is accepting applications for fiscal year (FY) 2018 Rural Opioid Technical Assistance Grants (Short Title: ROTA). The purpose of this program is to develop and disseminate training and technical assistance for rural communities on addressing opioid issues affecting these communities. It is expected that grantees will facilitate the identification of model programs, develop and update materials related to the prevention, treatment and recovery activities for opioid use disorder (OUD), and ensure that high-quality training is provided.